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See Article, pages 415–425Vitamin D in its active form, 1,25-(OH)2 vitamin D, has been
shown to play a role in various diseases, such as different types
of infectious and autoimmune diseases as well as cancers [1]. It
is estimated that one billion people worldwide are vitamin D
deﬁcient or insufﬁcient [2]. Sources of vitamin D are diet and die-
tary supplements as well as endogenously synthesised vitamin D
from 7-dehydrocholesterol following exposure to ultraviolet B
radiation [1]. To achieve the biologically active form, vitamin
D3 undergoes 25-hydroxylation in the liver and subsequent 1-
hydroxylation in the kidneys [3]. Meanwhile vitamin D has been
reported to control over 200 genes in a direct or indirect way.
Among those are genes regulating angiogenesis, apoptosis, cell
growth, proliferation and differentiation [4], mainly reducing cell
proliferation and inducing terminal differentiation [4,5]. Further-
more, immunomodulatory effects of 1,25-(OH)2 vitamin D are
well described, as monocytic cells upregulate vitamin D receptor
upon antigen exposure, enhancing innate immune responses. In
this view, vitamin D may also favour immune tolerance towards
the liver allograft as early vitamin D supplementation in patients
post-transplantation was associated with a reduced rate of acute
cellular rejection [6].
In the view of bile acid-dependent uptake of vitamin D and its
hepatic metabolism, it is reasonable to expect an association
between vitamin D status and both cholestatic and non-chole-
static chronic liver disease. Indeed, serum concentrations of
1,25-(OH)2 vitamin D are decreased in patients with cirrhosis
versus noncirrhotic patients [7,8] and a gradual decline has been
observed in cirrhotic patients according to increasing Child-Pugh
class [7] and clinical decompensation [9]. Recently, a signiﬁcant
correlation between lower 25-OH vitamin D levels and an
increasing stage of ﬁbrosis and severity of necroinﬂammatory
activity was observed in a population with genotype 1 chronic
hepatitis C [10]. Interestingly, reduced 25-OH vitamin D levels
can be found in patients with non-alcoholic fatty liver disease
(NAFLD) compared to controls with a close association to the his-
tological severity of hepatic steatosis, necroinﬂammation and
ﬁbrosis [11]. Since in this study 25-OH vitamin D was inversely
associated with NAFLD features independent of insulin resistanceJournal of Hepatology 20
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equate vitamin D status might contribute to the development and
progression of NAFLD. These ﬁndings were recently conﬁrmed in
children with biopsy-proven NAFLD, where low 25-OH vitamin D
levels were associated with increased likelihood of ﬁbrosis and
necroinﬂammation [12]. Independent of serum vitamin D levels,
alterations in the vitamin D receptor (VDR, NR1I1) gene have also
been described as an important event in a multitude of diseases,
among these are hepatic disorders such as primary biliary cirrho-
sis and autoimmune hepatitis [13,14].
In this issue of the Journal, Nakano and coworkers have inves-
tigated the impact of sunlight therapy on the progress of NAFLD
in rats [15]. In this study, phototherapy ameliorated insulin resis-
tance and hepatic steatosis caused by a choline-deﬁcient and
iron-supplemented L-amino acid-deﬁned (CDAA) diet. In particu-
lar, phototherapy improved histology with regard to hepatocyte
apoptosis, inﬂammation and ﬁbrosis, increased serum adiponec-
tin levels and led to a reduced hepatic expression of the proﬁbrot-
ic transforming growth factor (TGF)-b and the hepatic stellate cell
activation marker a-smooth muscle actin (SMA). A gradual
decrease of apolipoprotein E under CDAA diet was reversed by
phototherapy. Comparable to low 25-OH vitamin D levels
reported in human NAFLD [11], 25-OH vitamin D and 1,25-
(OH)2 vitamin D levels were signiﬁcantly lower in CDAA diet rats
compared to untreated controls. Of mechanistic interest, an ele-
vation of the circulating active form of vitamin D3 has been
observed after sunlight therapy and an intervention with vitamin
D3 supplementation ameliorated histology, in the same model, as
measured by a decreased hepatitis area. However, the effects of
phototherapy were less pronounced in leptin receptor-mutant
Zucker rats, a more obesity-related model of fatty liver disease.
The fact that hepatic steatosis and liver-to-body weight ratio
remains unchanged in this second model raises the question,
whether sunlight (and/or vitamin D) therapy is rather anti-
inﬂammatory and may have less metabolic or anti-steatotic
effects. Recent preliminary data from vitamin D receptor knock-
out mice point to the fact that the vitamin D status also impacts
on hepatic steatosis. In line with the beneﬁcial effect of vitamin D
observed in the CDAA model, vitamin D receptor knockout mice
spontaneously develop hepatic steatosis [16]. In this study, liver
steatosis was observed in 57% of VDR-/- mice under basal condi-
tions, while no steatosis was evidenced in VDR+/+ mice.
Whereas a variety of data suggest the potentially beneﬁcial
role of vitamin D in treatment of NAFLD, the underlying11 vol. 55 j 273–275
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mechanisms are less well established. Hepatocytes express only
low levels of VDR mRNA [17,18], so vitamin D effects on the liver
are most likely not conferred by direct signalling in parenchymal
liver cells. In contrast, non-parenchymal hepatic cells such as
sinusoidal endothelial cells, Kupffer cells and hepatic stellate cells
(HSC) do express VDR mRNA and functionally active VDR protein
[19]. More recent cell culture studies showed marked anti-
inﬂammatory and antiﬁbrotic effects of VDR-signalling in HSC.
During inﬂammatory liver injury after endotoxin injection the
activation of VDR signalling by vitamin D resulted in attenuation
of liver damage in vivo [20]. Besides these effects on non-paren-
chymal hepatic cells, vitamin D also activates intestinal ﬁbroblast
growth factor (Fgf) 15 (human ortholog FGF19) in mice, an intes-
tine-derived hormone that acts on liver to inhibit the hepatic
cholesterol 7a-hydroxylase (Cyp7a1) [21,22]. This Fgf-dependent
regulation of bile acid metabolism is conserved between rodents
and humans and the FGF19-mediated phosphorylation of the
hepatic FGF receptor (FGFR) 4 with subsequent activation of the
Erk1/2 pathway inhibits human CYP7A1 [23]. The central role
of CYP7A1 inhibition in hepatic dyslipidemia becomes evidentFig. 1. Vitamin D-mediated effects on fatty liver disease. Anti-inﬂammatory, anti-ﬁ
non-parenchymal hepatic cells (hepatic stellate cells, Kupffer cells, and lymphocytes)
7a-hydroxylase (CYP7A1) and on forkhead transcription factor 1 (FOXO1), a central me
ﬁbroblast growth factor 15/19 and hepatic FGF receptor 4 (FGFR4) signalling. Furtherm
adiponectin expression is activated by vitamin D treatment.
274 Journal of Hepatology 201from studies in mice with transgenic expression of Cyp7a1 in
the liver which prevents high fat diet-induced obesity and insulin
resistance [24].
Interestingly, insulin and FGF15/19 both target the PI 3-kinase
pathway and inhibit forkhead transcription factor 1 (FOXO1) the
latter represents a central mediator in the convergence of FGF
and insulin signalling pathways which functions as an integrator
of glucose and bile acid metabolism [24]. Increasing evidence
exists for the beneﬁcial effects of vitamin D on glucose metabo-
lism and insulin resistance in man. Low serum 25-OH vitamin
D is predictive of future glycemia and insulin resistance in non-
diabetic subjects [25] and inversely associated with metabolic
syndrome in the 1958 British Birth Cohort [26]. Furthermore,
low vitamin D levels have been associated in non-diabetic adults
with several markers of insulin resistance such as plasma glucose,
insulin, HOMA-IR and adiponectin [27,28]. A close correlation
between body mass index and 25-OH vitamin D level has been
described in which each BMI increase of 1 kg/m2 was associated
with a 1.3 nmol/L decrease in vitamin D [29]. The hepatic
response to FGF19 is impaired in NAFLD patients with insulinbrotic, and metabolic effects of vitamin D on parenchymal (hepatocytes) and
are induced in fatty livers. Metabolic effects of vitamin D on the cholesterol
diator in the insulin signalling pathway, are mediated via intestinal activation of
ore, apolipoprotein (APOE) expression is induced. In white adipose tissue (WAT),
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resistance (HOMA scoreP2.5) [30]. Both decreased vitamin D
levels and this impaired hepatic response to FGF19 may contrib-
ute to the dysregulation of lipid homeostasis in NAFLD. Most
interestingly, therapeutic intervention with vitamin D substitu-
tion leads to the amelioration of insulin resistance without affect-
ing insulin secretion [31,32]. All of these ﬁndings clearly support
a central role of vitamin D signalling in glucose homeostasis and
the metabolic syndrome and warrant further study of mechanis-
tic detail. A synopsis of vitamin D-mediated effects on the liver
and particularly fatty liver disease is given in Fig. 1.
Understanding the complex interplay between vitamin D sig-
nals and lipid/glucose metabolism and differentiating speciﬁc
metabolic effects from nonspeciﬁc anti-inﬂammatory properties
in fatty liver disease may open new therapeutic interventions
for the future in this constantly increasing threat to public health.
The ﬁrst conﬁrmation of therapeutic potency of sunlight therapy
and vitamin D in an animal model of fatty liver disease clearly
builds the basis for subsequent human therapeutic trials in
NAFLD. Vitamin D substitution represents a simple, cheap and
almost side effect-free candidate approach to reduce the burden
of end-stage liver failure and liver cancer in this frequent disease
entity for which medical interventions with proven longterm efﬁ-
cacy are still lacking.Conﬂict of interest
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